Introduction
Leading global biopharmaceutical company inaugurated its first U.S. manufacturing facility in Cranbury, New Jersey, investing over USD 30 million to produce 2 billion tablets annually, strengthening supply chains and expanding its global footprint.
Also Read: Vikram Solar: Stock jumps 13% after its net profits grow 484.2% in Q1
Share price movement of Biocon
On September 11, 2025, Biocon Ltd opened at ₹364.20, up 0.40% from its previous close of ₹363.95. The stock reached a high of ₹369.00 (1.45%) and a low of ₹364.20. By 11:00 AM, it traded at ₹365.40, a 0.40% increase, with a market cap of ₹48,852.65 crore.
Biocon Opens First U.S. Manufacturing Facility
Biocon Limited inaugurated its first U.S. manufacturing facility in Cranbury, New Jersey, through its wholly owned subsidiary Biocon Generics Inc. The Governor of New Jersey, Phil Murphy, attended the inauguration.
The facility was acquired from Eywa Pharma Inc. in 2023. Biocon invested over USD 30 million to develop the plant, which has an annual production capacity of 2 billion tablets.
A few products have already been commercialized from the site. The facility strengthens Biocon’s U.S. supply chain, diversifies its manufacturing base, and supports expansion of its global operations.
Stock performance of Biocon for Period of 1 week, 6 months, and 1 year
Biocon Ltd delivered a 2.06% return over the past week, it gained 12.7% in the past six months. The stock declined 5.48% over the past year.
Also Read: Kellton Tech Solutions: Stock jumps 7% after singing MoU with E-Group ICT Software Zrt
Shareholding pattern of Biocon
| Particulars | Jun 2025 | Mar 2025 | Dec 2024 |
| Promoter | 55% | 60.60% | 60.60% |
| FII | 7.00% | 5.70% | 5.70% |
| DII | 21.50% | 15.70% | 15.40% |
| Public | 16.90% | 17.80% | 18.10% |
| Others | 0.20% | 0.20% | 0.20% |
About Biocon
Biocon Limited (NSE: BIOCON) is a global biopharmaceutical company developing and commercializing biologics, biosimilars, and complex APIs, providing affordable therapies for diabetes, cancer, and autoimmune diseases across India, the U.S., Europe, and other markets.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Biocon Ltd share price going up today?
A: Biocon Ltd share price is rising after inaugurating its first U.S. manufacturing facility in Cranbury, New Jersey, through its subsidiary Biocon Generics Inc.
Q: What does Biocon Ltd specialize in?
A: Biocon Ltd specializes in developing and commercializing biologics, biosimilars, complex APIs, and generic formulations for diabetes, cancer, and autoimmune diseases globally.
Q: How much stake do promoters hold in Biocon Ltd stock?
A: Promoters hold a 55% stake in Biocon Ltd, reflecting significant control over company operations and strategic decisions.
